HK1042239B - Bupropion to treat viral diseases - Google Patents

Bupropion to treat viral diseases Download PDF

Info

Publication number
HK1042239B
HK1042239B HK02103897.6A HK02103897A HK1042239B HK 1042239 B HK1042239 B HK 1042239B HK 02103897 A HK02103897 A HK 02103897A HK 1042239 B HK1042239 B HK 1042239B
Authority
HK
Hong Kong
Prior art keywords
bupropion
herpes
virus
use according
treatment
Prior art date
Application number
HK02103897.6A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1042239A1 (en
Inventor
William Reindler Christopher
Original Assignee
Planisphere Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Planisphere Corp. filed Critical Planisphere Corp.
Publication of HK1042239A1 publication Critical patent/HK1042239A1/en
Publication of HK1042239B publication Critical patent/HK1042239B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
HK02103897.6A 1998-12-08 1999-12-07 Bupropion to treat viral diseases HK1042239B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13549498P 1998-12-08 1998-12-08
US60/135,494 1998-12-08
PCT/AU1999/001089 WO2000033827A1 (en) 1998-12-08 1999-12-07 Bupropion to treat viral diseases

Publications (2)

Publication Number Publication Date
HK1042239A1 HK1042239A1 (en) 2002-08-09
HK1042239B true HK1042239B (en) 2005-12-09

Family

ID=22468359

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02103897.6A HK1042239B (en) 1998-12-08 1999-12-07 Bupropion to treat viral diseases

Country Status (14)

Country Link
US (2) US6512011B1 (https=)
EP (1) EP1156791B1 (https=)
JP (1) JP4166955B2 (https=)
AT (1) ATE295159T1 (https=)
AU (1) AU762624B2 (https=)
BR (1) BR9916963A (https=)
CA (1) CA2349487C (https=)
DE (1) DE69925312T2 (https=)
ES (1) ES2242438T3 (https=)
HK (1) HK1042239B (https=)
MX (1) MXPA01005725A (https=)
NZ (1) NZ512716A (https=)
PT (1) PT1156791E (https=)
WO (1) WO2000033827A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030134905A1 (en) * 2002-01-11 2003-07-17 Reindler Christopher William Bupropion to treat viral diseases
DE102004063132A1 (de) * 2004-12-22 2006-07-06 Schmiegel, Wolff, Prof. Dr. Verwendung von Bupropion in Arzneimittel zur Behandlung von Hepatitis C
CN101534808A (zh) * 2005-06-27 2009-09-16 拜维尔实验室国际有限公司 丁氨苯丙酮盐的改良释放配制品
GB2477584A (en) * 2010-02-04 2011-08-10 Biocopea Ltd A compound for use in treating an acute viral infection
WO2011018653A2 (en) * 2009-08-10 2011-02-17 Biocopea Limited Treatment of viral infections
CN108721262A (zh) * 2017-04-13 2018-11-02 中国科学院武汉病毒研究所 安非他酮在制备治疗或预防流感病毒感染的药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438138A (en) * 1982-12-06 1984-03-20 Burroughs Wellcome Co. Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
US4507323A (en) * 1984-07-25 1985-03-26 Burroughs Wellcome Co. Treatment of psychosexual dysfunctions
US5753712A (en) * 1994-02-18 1998-05-19 Pinsker; Walter Treatment of migraine headaches and formulations
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer

Also Published As

Publication number Publication date
DE69925312D1 (de) 2005-06-16
ATE295159T1 (de) 2005-05-15
BR9916963A (pt) 2002-03-05
JP4166955B2 (ja) 2008-10-15
DE69925312T2 (de) 2006-03-09
EP1156791A1 (en) 2001-11-28
PT1156791E (pt) 2005-08-31
US6512011B1 (en) 2003-01-28
EP1156791B1 (en) 2005-05-11
US20020173551A1 (en) 2002-11-21
JP2002531495A (ja) 2002-09-24
CA2349487C (en) 2007-09-11
WO2000033827A1 (en) 2000-06-15
CA2349487A1 (en) 2000-06-15
ES2242438T3 (es) 2005-11-01
MXPA01005725A (es) 2003-07-14
EP1156791A4 (en) 2002-05-02
AU1762900A (en) 2000-06-26
HK1042239A1 (en) 2002-08-09
AU762624B2 (en) 2003-07-03
NZ512716A (en) 2003-10-31

Similar Documents

Publication Publication Date Title
US4507323A (en) Treatment of psychosexual dysfunctions
KR20100036390A (ko) 비뇨생식기 장애 치료용 화합물 및 그 방법
US20100323952A1 (en) Nucleoside Analogs in Combination Therapy of Herpes Simplex Infections
EP1156791B1 (en) Bupropion to treat viral diseases
EP0171227B1 (en) Use of propiophenone compound
US20040029973A1 (en) Bupropion to treat viral diseases
GB2340037A (en) Compositions comprising bupropion for the treatment of premature ejaculation
US4751236A (en) Method for treating genital herpes
CA2244268C (en) Nucleoside analogs in combination therapy of herpes simplex infections
US9610295B2 (en) Method for treating erectile dysfunction
HK1016475B (en) Nucleoside analogs in combination therapy of herpes simplex infections
CA2174240A1 (en) Use of peniclorin for the treatment of posttherapeutic neuralgia
CA2080130A1 (en) Remedy for obstructive pulmonary diseases

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20091207